DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY

Conference contribution


Publication Details

Author(s): Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Assudani D, Kumke T, Ink B, Mcinnes I
Publisher: BMJ PUBLISHING GROUP
Publishing place: LONDON
Publication year: 2019
Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES
Pages range: 127-128
ISSN: 0003-4967
eISSN: 1468-2060


FAU Authors / FAU Editors

Schett, Georg Prof. Dr. med.
Lehrstuhl für Innere Medizin III


External institutions with authors

Harvard University
NYU Langone Medical Center
UCB Pharma Ltd
University of California, San Diego
University of Glasgow
University of Manchester
University of Rochester (UR)


How to cite

APA:
Ritchlin, C.T., Kavanaugh, A., Merola, J.F., Schett, G., Scher, J.U., Warren, R.B.,... Mcinnes, I. (2019). DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 127-128). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:
Ritchlin, Christopher T., et al. "DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 127-128.

BibTeX: 

Last updated on 2019-16-07 at 08:39